- Home
- YQ vs CLRB Comparison
YQ vs CLRB Comparison
Compare YQ & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- CLRB
- Stock Information
- Founded
- YQ 2012
- CLRB 2002
- Country
- YQ China
- CLRB United States
- Employees
- YQ N/A
- CLRB N/A
- Industry
- YQ Other Consumer Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- CLRB Health Care
- Exchange
- YQ Nasdaq
- CLRB Nasdaq
- Market Cap
- YQ 15.2M
- CLRB 12.5M
- IPO Year
- YQ 2020
- CLRB N/A
- Fundamental
- Price
- YQ $2.14
- CLRB $7.90
- Analyst Decision
- YQ
- CLRB Hold
- Analyst Count
- YQ 0
- CLRB 2
- Target Price
- YQ N/A
- CLRB N/A
- AVG Volume (30 Days)
- YQ 66.3K
- CLRB 1.3M
- Earning Date
- YQ 06-10-2025
- CLRB 08-12-2025
- Dividend Yield
- YQ N/A
- CLRB N/A
- EPS Growth
- YQ N/A
- CLRB N/A
- EPS
- YQ N/A
- CLRB N/A
- Revenue
- YQ $25,546,613.00
- CLRB N/A
- Revenue This Year
- YQ N/A
- CLRB N/A
- Revenue Next Year
- YQ N/A
- CLRB N/A
- P/E Ratio
- YQ N/A
- CLRB N/A
- Revenue Growth
- YQ N/A
- CLRB N/A
- 52 Week Low
- YQ $1.26
- CLRB $6.50
- 52 Week High
- YQ $3.19
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- YQ 59.17
- CLRB 40.04
- Support Level
- YQ $2.04
- CLRB $9.60
- Resistance Level
- YQ $2.39
- CLRB $10.19
- Average True Range (ATR)
- YQ 0.21
- CLRB 1.57
- MACD
- YQ 0.01
- CLRB -0.50
- Stochastic Oscillator
- YQ 58.33
- CLRB 11.58
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.